Genmab Combination Improves Survival in Phase 3 Cancer Trial
Genmab reported positive Phase 3 results for petosemtamab plus Keytruda as first-line treatment for PD-L1-positive recurrent or metastatic head and neck cancer. The combination significantly improved overall survival.
Story updates
03:54:05 PM UTC
SquawkNews
By Natalie WegerGenmab A/S released positive topline results from its Phase 3 trial of an antibody that helps patients with metastatic head and neck cancer.Shares of Genmab rose 27% to $56.67 on Wednesday, and earlier hit an all-time high of $56.75. The stock is up 84% year to date.The antibody, ca…
WASHINGTON (dpa-AFX) - Genmab A/S (GMAB) reported positive results form a Phase 3 trial evaluating Petosemtamab plus Keytruda (pembrolizumab) as a first-line treatment for patients with PD-L1 positive recurrent or metastatic head and neck cancer. The combination significantly improved overall survi…